Fiduciary Trust Co. Has $954,000 Position in GlaxoSmithKline PLC (NYSE:GSK)

Fiduciary Trust Co. held its position in GlaxoSmithKline PLC (NYSE:GSK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,129 shares of the pharmaceutical company’s stock at the end of the 2nd quarter. Fiduciary Trust Co.’s holdings in GlaxoSmithKline PLC were worth $954,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Russell Investments Group Ltd. acquired a new stake in GlaxoSmithKline PLC in the 1st quarter valued at approximately $578,000. Advisory Services Network LLC acquired a new stake in GlaxoSmithKline PLC in the 1st quarter valued at approximately $137,000. GFS Advisors LLC grew its holdings in GlaxoSmithKline PLC by 105.2% in the 1st quarter. GFS Advisors LLC now owns 10,869 shares of the pharmaceutical company’s stock valued at $458,000 after buying an additional 5,573 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in GlaxoSmithKline PLC by 15.2% in the 1st quarter. Sequoia Financial Advisors LLC now owns 6,500 shares of the pharmaceutical company’s stock valued at $274,000 after buying an additional 859 shares during the last quarter. Finally, Vantage Investment Partners LLC grew its holdings in GlaxoSmithKline PLC by 589.6% in the 1st quarter. Vantage Investment Partners LLC now owns 269,408 shares of the pharmaceutical company’s stock valued at $11,358,000 after buying an additional 230,339 shares during the last quarter. 9.28% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Fiduciary Trust Co. Has $954,000 Position in GlaxoSmithKline PLC (NYSE:GSK)” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/fiduciary-trust-co-holds-holdings-in-glaxosmithkline-plc-gsk/1602062.html.

GSK has been the topic of a number of research analyst reports. Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $44.67.

GlaxoSmithKline PLC (NYSE:GSK) opened at 40.58 on Friday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54. The company has a market cap of $99.18 billion, a P/E ratio of 40.10 and a beta of 1.03. The company’s 50 day moving average price is $39.76 and its 200 day moving average price is $41.75.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities research analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.